Sanofi SA (NASDAQ:SNY)

45.43
Delayed Data
As of 3:59pm ET
 +0.02 / +0.04%
Today’s Change
37.43
Today|||52-Week Range
45.62
+4.65%
Year-to-Date
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
Mar 20 / Zacks.com - Paid Partner Content
Should Value Investors Consider Sanofi (SNY) Stock Now?
Mar 13 / Zacks.com - Paid Partner Content
Can Dermira Stock Keep Soaring?
Mar 19 / MotleyFool.com - Paid Partner Content
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion
Mar 12 / Zacks.com - Paid Partner Content
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
Mar 18 / Zacks.com - Paid Partner Content
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
Mar 11 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
Mar 13 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close45.41
Today’s open45.07
Day’s range45.07 - 45.49
Volume905,184
Average volume (3 months)1,019,342
Market cap$112.5B
Data as of 3:59pm ET, 03/21/2019

Growth & Valuation

Earnings growth (last year)-3.51%
Earnings growth (this year)+4.55%
Earnings growth (next 5 years)+8.14%
Revenue growth (last year)+2.83%
P/E ratio23.2
Price/Sales2.68
Price/Book1.67

Competitors

 Today’s
change
Today’s
% change
AZNAstraZeneca-0.07-0.16%
GSKGlaxoSmithKline+0.43+1.05%
ABBVAbbVie+0.81+1.01%
NVONovo Nordisk+0.33+0.63%
Data as of 4:02pm ET, 03/21/2019

Financials

Next reporting dateApril 26, 2019
EPS forecast (this quarter)$0.78
Annual revenue (last year)$40.7B
Annual profit (last year)$5.1B
Net profit margin12.53%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Director
Olivier Brandicourt
Chief Financial Officer &
Executive Vice President
Jean-Baptiste Chasseloup de Chatillon
Corporate headquarters
Paris, Ile-de-france

Forecasts